Pathfinders in Biopharma
RBC Capital Markets
Categorias: Noticias y política
Añadir a Mi Lista
Escuchar el último episodio:
Episodios anteriores
-
45 - Former Investor Who Chose Broadcasting Over Biotech ETFsMon, 30 Sep 2024 - 0h
-
44 - Can AI Solve Molecule Mysteries that will Unlock Simpler Drug Discovery?Thu, 29 Aug 2024 - 0h
-
43 - Shots-on-Goal Licensing Company Aims for BreakthroughsFri, 19 Jul 2024 - 0h
-
42 - Why Biopharma Needs to Tell Better Stories on Novel DrugsThu, 11 Jul 2024 - 0h
-
41 - Venture capital velocity: What’s driving renewed momentum in biotech?Mon, 08 Jul 2024 - 0h
-
40 - Pharma Understands Phase One Data – But Does the Market?Fri, 21 Jun 2024 - 0h
-
39 - Davern Capital sees GLP-1 Opportunities Beyond ObesityFri, 14 Jun 2024 - 0h
-
38 - Betting on Healthcare’s Future Hits – and MissesMon, 10 Jun 2024 - 0h
-
37 - Innovation and an Aging Population Drive MedTechWed, 05 Jun 2024 - 0h
-
36 - Biopharma Investors See Opportunities in Targeted Treatments and Gene EditingMon, 03 Jun 2024 - 0h
-
35 - Biotech with a Mission to Target Unmet Cancer NeedsFri, 31 May 2024 - 0h
-
33 - The M&A Pool Set to Accelerate Biotech InnovationWed, 03 Apr 2024 - 0h
-
32 - How PIPEs finally unblocked biotech’s funding flowsFri, 29 Mar 2024 - 0h
-
31 - Disruptive Forces in Healthcare: Why HCIT is finally set to bounce backThu, 07 Mar 2024 - 0h
-
30 - Will the Biotech Rebound Run into Pricing Policy Obstacles?Tue, 27 Feb 2024 - 0h
-
29 - Few IPOs but plenty of follow-on for biotech in 2023Mon, 22 Jan 2024 - 0h
-
28 - U.S. Outlook: Will the US economy achieve a soft landing in 2024?Fri, 29 Dec 2023 - 0h
-
27 - Raising Venture Capital: A New Playbook for A New Era in BiotechWed, 22 Nov 2023 - 0h
-
26 - ECM: Robust End to Year, Despite Previous VolatilityTue, 31 Oct 2023 - 0h
-
25 - Biotech Halftime Report: A Winding Road AheadTue, 26 Sep 2023 - 0h
-
24 - The Urgent Need to Address the Youth Mental Health LandscapeThu, 17 Aug 2023 - 0h
-
23 - Website Traffic Reveals Biopharma Sales TrendsMon, 07 Aug 2023 - 0h
-
22 - When to Call it Quits: VCs Making Tough Decisions in a Tough MarketThu, 13 Jul 2023 - 0h
-
21 - How Biotech M&A is Redefining the Strategic LandscapeFri, 23 Jun 2023 - 0h
-
20 - Healthcare Should Get Ready for ‘Fast and Furious’ M&AThu, 08 Jun 2023 - 0h
-
19 - Innovation and Growth: Key Ingredients to Healthcare M&AWed, 07 Jun 2023 - 0h
-
18 - Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?Fri, 02 Jun 2023 - 0h
-
17 - Global Blood Therapeutics Commitment to Sickle-Cell InnovationMon, 22 May 2023 - 0h
-
16 - Is This the Breakthrough Moment for Genetic Medicine?Thu, 13 Apr 2023 - 0h
-
15 - The Hidden Revolution Set to Turn US Healthcare on its HeadThu, 26 Jan 2023 - 0h
-
14 - The Big Picture for BiotechTue, 13 Dec 2022 - 0h
-
13 - Why Biopharma Investment Requires a Different MindsetTue, 22 Nov 2022 - 0h
-
12 - The Optimism Behind the Biopharma MarketMon, 03 Oct 2022 - 0h
-
11 - Biotech Investors: How to Find Value in a Bear MarketMon, 21 Mar 2022 - 0h
-
10 - A call to action: Global Blood Therapeutics on tackling orphan diseaseWed, 08 Dec 2021 - 0h
-
9 - Ionis: Raising The Bar For ESGThu, 28 Oct 2021 - 0h
-
8 - Biotech and Big Pharma: Blueprint for Successful PartnershipThu, 30 Sep 2021 - 0h
-
7 - What’s Material in ESG for Biopharma Firms?Tue, 04 May 2021 - 0h
-
6 - Inside Track: Behind the Scenes of a Major Biotech SPACMon, 26 Apr 2021 - 0h
-
5 - Biotech SPACs: A new route to going publicFri, 12 Mar 2021 - 0h
-
4 - Vida Ventures: Powering Breakthroughs in BiopharmaMon, 21 Dec 2020 - 0h
-
3 - 5AM Ventures: Fueling the Next Generation of InnovatorsMon, 21 Dec 2020 - 0h
-
2 - Biotech IPOs: Navigating the New LandscapeThu, 10 Dec 2020 - 0h
-
1 - Biotech IPOs: New Steps to Success on the Road to Going PublicTue, 01 Dec 2020 - 0h
Mostrar más episodios
5
